Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.

Hayashi T, Yamamoto S, Miyata Y, Takeda M, Abe M, Wada M, Iino K, Akechi T, Imamura CK, Okuyama A, Ozawa K, Kim YI, Sasaki H, Satomi E, Tanaka R, Nakajima TE, Nakamura N, Nishimura J, Noda M, Hayashi K, Higashi T, Boku N, Matsumoto K, Matsumoto Y, Okita K, Yamamoto N, Aogi K, Iihara H

Open source

DOI: 10.1007/s10147-024-02623-y
Published: 2024 Nov
Container: International journal of clinical oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s10147-024-02623-y,
  title = {Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.},
  author = {Hayashi T and Yamamoto S and Miyata Y and Takeda M and Abe M and Wada M and Iino K and Akechi T and Imamura CK and Okuyama A and Ozawa K and Kim YI and Sasaki H and Satomi E and Tanaka R and Nakajima TE and Nakamura N and Nishimura J and Noda M and Hayashi K and Higashi T and Boku N and Matsumoto K and Matsumoto Y and Okita K and Yamamoto N and Aogi K and Iihara H},
  year = {2024},
  journal = {International journal of clinical oncology},
  doi = {10.1007/s10147-024-02623-y},
  url = {https://doi.org/10.1007/s10147-024-02623-y}
}

RIS

TY  - JOUR
TI  - Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.
AU  - Hayashi T
AU  - Yamamoto S
AU  - Miyata Y
AU  - Takeda M
AU  - Abe M
AU  - Wada M
AU  - Iino K
AU  - Akechi T
AU  - Imamura CK
AU  - Okuyama A
AU  - Ozawa K
AU  - Kim YI
AU  - Sasaki H
AU  - Satomi E
AU  - Tanaka R
AU  - Nakajima TE
AU  - Nakamura N
AU  - Nishimura J
AU  - Noda M
AU  - Hayashi K
AU  - Higashi T
AU  - Boku N
AU  - Matsumoto K
AU  - Matsumoto Y
AU  - Okita K
AU  - Yamamoto N
AU  - Aogi K
AU  - Iihara H
PY  - 2024
JO  - International journal of clinical oncology
DO  - 10.1007/s10147-024-02623-y
UR  - https://doi.org/10.1007/s10147-024-02623-y
ER  -

APA

T, H., S, Y., Y, M., M, T., M, A., M, W., K, I., T, A., CK, I., A, O., K, O., YI, K., H, S., E, S., R, T., TE, N., N, N., J, N., M, N., K, H., T, H., N, B., K, M., Y, M., K, O., N, Y., K, A., & H, I. (2024). Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology.. International journal of clinical oncology. https://doi.org/10.1007/s10147-024-02623-y

Source records

pubmed · retrieved 2026-09-26T20:35:50.426Z